Estudos Randomizados
Perspectiva | A necessidade de um maior pragmatismo nos estudo clínicos cardiovasculares.
20 Mai, 2022 | 14:00hThe need for increased pragmatism in cardiovascular clinical trials – Nature Reviews Cardiology (se o acesso a este link for pago, tente este)
Conteúdo relacionado: A roadmap of strategies to support cardiovascular researchers: from policy to practice – Nature Reviews Cardiology (se o acesso a este link for pago, tente este)
Comentário no Twitter
In our latest Review, @ShahzebKhanMD and colleagues discuss the need for increased pragmatism in #cardiovascular clinical trials: https://t.co/LUlrPKusAk pic.twitter.com/cxAYmD2nyS
— Nature Reviews Cardiology (@NatRevCardiol) May 17, 2022
Revisão de escopo | Diferentes tipos de ensaios clínicos aplicados à medicina personalizada.
20 Mai, 2022 | 13:35hStudy designs for clinical trials applied to personalised medicine: a scoping review – BMJ Open
Visualizando danos em publicações de estudos controlados randomizados: consenso e recomendações.
18 Mai, 2022 | 16:47hComentário: Visualising harms: barely scratching the surface – The BMJ
Estudo randomizado | Eficácia e segurança da fenfluramina no tratamento de convulsões associadas à síndrome de Lennox-Gastaut.
17 Mai, 2022 | 11:40hComentários:
Fenfluramine Found Effective for Treatment of Lennox-Gastaut Syndrome Seizures – NeurologyToday
Fenfluramine Seems Effective for Lennox-Gastaut Syndrome – HealthDay
Comentário no Twitter
In this randomized clinical trial, fenfluramine was a safe and effective treatment option for patients with Lennox-Gastaut syndrome. https://t.co/Ukopx9cV9r @Zogenix pic.twitter.com/dRetoOZSiB
— JAMA Neurology (@JAMANeuro) May 2, 2022
Estudo randomizado e revisão sistemática | Raspagem endometrial para aumentar as taxas de nascidos vivos em mulheres submetidas à primeira tentativa de fertilização in vitro.
13 Mai, 2022 | 12:26hConteúdos relacionados:
Estudo randomizado de fase 2 | Terapia antifator de necrose tumoral (anti-TNF) para doença de Dupuytren em estágio inicial.
10 Mai, 2022 | 14:16hComunicado de imprensa: Breakthrough in treatment for Dupuytren’s disease – University of Oxford
Comentário: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian
Comentário no Twitter
NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4
— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022
Estudo randomizado | Reloxaliase vs. placebo na hiperoxalúria entérica.
10 Mai, 2022 | 14:14hRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Comentário no Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022
Estudo randomizado | Eficácia e segurança da difelikefalina em pacientes com prurido moderado a grave recebendo hemodiálise.
10 Mai, 2022 | 14:09h
Comentário no Twitter
This RCT found difelikefalin, a κ-opioid receptor agonist, improved moderate to severe pruritus in Japanese hemodialysis patients. Difelikefalin is expected to be a new option for the treatment of uremic pruritus in patients with end stage kidney disease. https://t.co/cXqNx4QIaS pic.twitter.com/7QdA9GoLwN
— JAMA Network Open (@JAMANetworkOpen) May 5, 2022
Estudos de não inferioridade: compreendendo os conceitos.
3 Mai, 2022 | 16:08hNon-Inferiority Trials: Understanding the Concepts – Students 4 Best Evidence
Conteúdos relacionados:
Non-inferiority trials in cardiology: what clinicians need to know – Heart